Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Vertex Pharmaceuticals revenue
Vertex Pharmaceuticals's revenue is $11.0 billion.
What is Vertex Pharmaceuticals's revenue?
- Vertex Pharmaceuticals's revenue growth from 2001 to 2024 is 12,819.68%.
- Vertex Pharmaceuticals has 3,400 employees, and the revenue per employee ratio is $3,241,205.
- Vertex Pharmaceuticals's peak quarterly revenue was $2.9B in 2024(q4).
- Vertex Pharmaceuticals peak revenue was $11.0B in 2024.
- Vertex Pharmaceuticals annual revenue for 2023 was 9.9B, 10.51% growth from 2022.
- Vertex Pharmaceuticals annual revenue for 2024 was 11.0B, 11.66% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Vertex Pharmaceuticals historical revenue
Vertex Pharmaceuticals's peak revenue was $11.0B in 2024. The peak quarterly revenue was $2.9B in 2024(q4).
Vertex Pharmaceuticals's revenue increased from $85.3m in 2001 to $11.0B currently. That's a 12,819.68% change in annual revenue.
Vertex Pharmaceuticals annual revenue
Vertex Pharmaceuticals annual revenue over time
| Fiscal year / year | Vertex Pharmaceuticals revenue |
|---|---|
| 2009 | $101.9M |
| 2010 | $143.4M |
| 2011 | $1.4B |
| 2012 | $1.5B |
| 2013 | $1.2B |
| 2014 | $580.4M |
| 2015 | $1.0B |
| 2016 | $1.7B |
| 2017 | $2.5B |
| 2018 | $3.0B |
| 2019 | $4.2B |
| 2020 | $6.2B |
| 2021 | $7.6B |
| 2022 | $8.9B |
| 2023 | $9.9B |
| 2024 | $11.0B |
Rate Vertex Pharmaceuticals' financial transparency
Vertex Pharmaceuticals annual growth
Vertex Pharmaceuticals saw the greatest revenue growth in 2011, when revenue increased by 883.91%.
Vertex Pharmaceuticals had the lowest revenue growth in 2014, when revenue changed by -52.11%.
Vertex Pharmaceuticals annual growth rate over time
| Year | Vertex Pharmaceuticals growth |
|---|---|
| 2009 | -42%↓ |
| 2010 | 41%↑ |
| 2011 | 884%↑ |
| 2012 | 8%↑ |
| 2013 | -21%↓ |
| 2014 | -52%↓ |
| 2015 | 78%↑ |
| 2016 | 65%↑ |
| 2017 | 46%↑ |
| 2018 | 22%↑ |
| 2019 | 37%↑ |
| 2020 | 49%↑ |
| 2021 | 22%↑ |
| 2022 | 18%↑ |
| 2023 | 11%↑ |
| 2024 | 12%↑ |
Vertex Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Vertex Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2013 | - | - | $221.7M | $351.2M |
| 2014 | $118.5M | $138.4M | $179.0M | $144.6M |
| 2015 | $138.5M | $166.1M | $309.8M | $417.9M |
| 2016 | $398.1M | $431.6M | $413.8M | $458.7M |
| 2017 | $714.7M | $544.1M | $578.2M | $651.6M |
| 2018 | $640.8M | $752.2M | $784.5M | $870.1M |
| 2019 | $858.4M | $941.3M | $949.8M | $1.4B |
| 2020 | $1.5B | $1.5B | $1.5B | $1.6B |
| 2021 | $1.7B | $1.8B | $2.0B | $2.1B |
| 2022 | $2.1B | $2.2B | $2.3B | $2.3B |
| 2023 | $2.4B | $2.5B | $2.5B | $2.5B |
| 2024 | $2.7B | $2.6B | $2.8B | $2.9B |
Vertex Pharmaceuticals jobs nearby
Do you work at Vertex Pharmaceuticals?
Is Vertex Pharmaceuticals transparent about its revenue structure?
Vertex Pharmaceuticals financial information
| CEO | Reshma Kewalramani M.d |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 3,400 |
| Date Founded | 1989 |
| Headquarters | Boston, Massachusetts |
| Number of Locations | 6 |
| Revenue | $11.0B |
| Net Income | $3,322,000,000 |
| Gross Proft | $9.5B (2024) |
| PE Ratio | -91.38 |
| Tax Rate | 3.2% |
| Market Capitalization | $48.9B |
| Total Assets | $18,150,900,000 |
| Ticker | VRTX |
Vertex Pharmaceuticals jobs you might like
Vertex Pharmaceuticals financing
Vertex Pharmaceuticals received early financing of $5.8M on 1989-07-17.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $5.8M | 07/1989 |
| Post Ipo Equity | $2.4M | 03/2009 |
| Post Ipo Equity | $35M | 09/2009 |
| Post Ipo Debt | $120M | 09/2009 |
| Post Ipo Equity | $443M | 12/2009 |
| Post Ipo Equity | $50M | 05/2022 |
Vertex Pharmaceuticals investors
| Investors | Security type |
|---|---|
| New Enterprise Associates (NEA) | Series Unknown |
| Norwest Venture Partners | Series Unknown |
| J.H. Whitney & Co. LLC | Series Unknown |
| Greylock Partners | Series Unknown |
| Janssen Belgium | Post Ipo Equity |
| The Goldman Sachs Group, Inc. | Post Ipo Equity |
| JPMorgan Chase & Co. | Post Ipo Equity |
| Bank of America Merrill Lynch | Post Ipo Equity |
| Morgan Stanley | Post Ipo Equity |
Vertex Pharmaceuticals competitors
Vertex Pharmaceuticals's top competitor, Johnson & Johnson, earned an annual revenue of $88.8B.
Vertex Pharmaceuticals's smallest competitor is Axio Research with revenue of $5.4M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Johnson & Johnson | $76,686 | $88.8B | 134,500 | 1,829 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 879 |
| Merck | $90,328 | $64.2B | 74,000 | 1,534 |
| Amgen | $93,349 | $33.4B | 22,000 | 702 |
| Regeneron | $85,589 | $14.2B | 9,123 | 390 |
| Sanofi Genzyme | $84,495 | $4.6B | 12,000 | - |
| Pfizer | $70,868 | $63.6B | 78,500 | 597 |
| Novartis | $112,479 | $51.7B | 110,000 | 381 |
| Boehringer Ingelheim | $106,981 | $17.2B | 52,391 | 376 |
| Bristol-Myers Squibb | $101,824 | $48.3B | 30,000 | 2,329 |
Vertex Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Vertex Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Vertex Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Vertex Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Vertex Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Vertex Pharmaceuticals. The data presented on this page does not represent the view of Vertex Pharmaceuticals and its employees or that of Zippia.
Vertex Pharmaceuticals may also be known as or be related to Vertex Pharmaceuticals, Vertex Pharmaceuticals Inc, Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals, Inc and Vertex Pharmaceuticals, Inc.